This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of nasal cavity and middle ear비강 및 중이의 악성신생물 (비강·중이암)

📋 Contents and key points
A.Classification codes — C30 (Malignant neoplasm of nasal cavity and middle ear)
B.Synonyms — Nasal cavity cancer, nasal squamous cell carcinoma, nasal adenocarcinoma, middle ear cancer, nasal NK/T-cell lymphoma
C.Adult onset — Very high (mainly in their 50s–70s; somewhat earlier onset in occupational groups exposed to wood dust)
1.History — Association between wood dust and nasal adenocarcinoma in the UK in the 1960s; establishment of middle ear cancer epidemiology; elucidation of the roles of HPV and EBV
2.Causes — Wood, leather, and nickel dust (nasal adenocarcinoma), smoking, chronic otitis media (middle ear cancer), HPV, radiation
3.Genetics — TP53, KRAS, EGFR; molecular features of nasal squamous cell carcinoma; EBV-associated nasal NK/T-cell lymphoma
4.Epidemiology — About 3% of head and neck cancers; male predominance; occupational cancer in wood and leather industry workers
5.Pathophysiology — Dust/irritants → nasal mucosal injury, squamous metaplasia → dysplasia → invasion; squamous cell carcinogenesis
6.Symptoms — Unilateral nasal obstruction, epistaxis, postnasal drip, facial pain, ocular symptoms, hearing loss (middle ear cancer)
7.Signs — Intranasal mass, facial asymmetry, trigeminal nerve palsy, cervical lymphadenopathy, conductive hearing loss
8.Screening — No standard screening; regular nasal endoscopic surveillance for high-risk groups with occupational exposure (wood, nickel)
9.Diagnosis — Nasal endoscopic biopsy, CT/MRI (evaluation of skull base invasion), PET-CT, AJCC TNM 8th edition staging
10.Treatment — Surgical resection (endoscopic or open); radiotherapy; cisplatin-based concurrent chemoradiotherapy
11.Prognosis — 5-year survival about 50–60% for squamous cell carcinoma; about 40–60% for adenocarcinoma; poor prognosis for middle ear cancer
12.Prevention — Blocking occupational dust exposure (dust masks, ventilation), smoking cessation, treatment of chronic otitis media
13.References — NCCN Head and Neck Cancers guidelines, 10 references on the epidemiology and treatment of nasal cavity and middle ear cancer

Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date


A. Classification codes

CategoryDetails
ICD-10 codeC30 — Malignant neoplasm of nasal cavity and middle ear
SubcodesC30.0 nasal cavity, C30.1 middle ear
Special Copayment Reduction codeV193
Main histological typesSquamous cell carcinoma (SCC, about 50% in the nasal cavity), adenocarcinoma (about 15–20% in the nasal cavity, especially wood dust-related), transitional cell carcinoma, malignant melanoma, olfactory neuroblastoma/esthesioneuroblastoma, adenocarcinoma of the middle ear
NoteNasal NK/T-cell lymphoma is classified separately as lymphoma (C86.0) but is included in the differential diagnosis of nasal malignancies

B. Synonyms

Nasal cavity cancer, nasal squamous cell carcinoma, nasal adenocarcinoma (intestinal and non-intestinal types), middle ear carcinoma, ear canal carcinoma, esthesioneuroblastoma (Kadish classification), nasal mucosal melanoma. In clinical practice, nasal cavity cancer and paranasal sinus cancer (C31) are anatomically adjacent and often occur together, so the two sites together are referred to as sinonasal malignancy.

C. Adult onset

Nasal cavity and middle ear cancer is a disease with a very high frequency of adult onset, with a median age at diagnosis of 50–70 years. Wood dust-related adenocarcinoma occurs mainly in the 40s–60s, when occupational exposure accumulates. Middle ear cancer is mainly diagnosed in people in their 40s–60s with a history of chronic otitis media. Occurrence in children is rare.


1. History

The most important epidemiologic discovery in the history of nasal cavity and middle ear malignancies is the elucidation of the causal relationship between wood dust and nasal adenocarcinoma. In 1965, Acheson et al. in the UK published in the Lancet the striking epidemiologic finding that the incidence of nasal adenocarcinoma among woodworkers and furniture makers in the Oxfordshire furniture-making area (Buckinghamshire) was 500–1,000 times that of the general population. Further studies confirmed that nasal adenocarcinoma clusters among woodworkers exposed to hardwood dust (oak, beech, etc.), and this finding became the basis for the International Agency for Research on Cancer (IARC) designating wood dust a Group 1 carcinogen.

The epidemiology of middle ear cancer is based on relatively small studies, and its association with chronic suppurative otitis media has been described in clinical observations since the late 19th century. Occupational exposure to radioactive substances (radium 225, etc.) is also known to be associated with nasal osteosarcoma and adenocarcinoma. An increase in squamous cell carcinoma of the nasal cavity and maxillary sinus among nickel refining workers was confirmed after the 1939 report by Bridge et al., and IARC also classifies nickel as a Group 1 carcinogen. The association of nasal NK/T-cell lymphoma with EBV (Epstein-Barr virus) was confirmed by molecular biological techniques in the 1990s, and it occurs at relatively high frequency especially in East Asia (Korea, China, Japan) and Latin America.

In the history of treatment, the development of endoscopic sinonasal surgery techniques (1990s–2000s) helped secure the extent of resection while preserving function compared with open surgery. The introduction of proton therapy and carbon ion therapy opened new possibilities for minimizing normal tissue damage in sinonasal malignancies invading the skull base.

2. Causes

Occupational dust exposure

Wood dust is the strongest occupational risk factor for nasal adenocarcinoma, with hardwood (oak, beech, mahogany) dust more dangerous than softwood. The risk of nasal adenocarcinoma increases markedly among workers in wood processing, furniture manufacturing, and carpentry. Leather dust is also associated with nasal adenocarcinoma, with clusters reported among shoemaking and leather processing workers. Nickel dust or fumes are associated with nasal squamous cell carcinoma and maxillary sinus cancer. Exposure to chromium compounds also carries a similar risk.

Other risk factors

Smoking is a general risk factor for nasal cavity and paranasal sinus cancer. HPV (especially HPV16 and 18) is detected in a portion of sinonasal cancers, and HPV-positive nasal cancer has been reported to have a better prognosis. Chronic otitis media (chronic suppurative otitis media) is an important risk factor for squamous cell carcinoma of the middle ear, with chronic inflammation inducing squamous dysplasia in the middle ear mucosa over decades. A history of radiation exposure, nasal polyps, and inverted papilloma are also risk factors for nasal cancer. Inverted papilloma transforms into squamous cell carcinoma in about 5–10%.

3. Genetics

The molecular genetics of nasal squamous cell carcinoma are similar to those of head and neck squamous cell carcinoma (HNSCC), with TP53 variants, CDKN2A (p16) loss, EGFR overexpression/amplification, PIK3CA variants, and CCND1 amplification observed. In HPV-related nasal cancer, loss of TP53 and RB1 function caused by HPV E6/E7 is the main molecular mechanism, and p16 overexpression on immunohistochemistry is used as a surrogate marker of HPV positivity. Nasal adenocarcinoma (intestinal-type) shows molecular features similar to gastrointestinal adenocarcinoma (CDX2 expression, MUC2 expression), and characteristic DNA damage patterns have been reported in wood dust-related adenocarcinoma.

Esthesioneuroblastoma is a neuroendocrine tumor in which EGFR variants and IDH2 variants have been reported. Nasal malignant melanoma shows BRAF variants (about 15%), KIT variants (about 10%), and NRAS variants, with molecular features somewhat different from cutaneous melanoma. In EBV-associated nasal NK/T-cell lymphoma, EBV EBER positivity is diagnostic, and activation of the JAK/STAT signaling pathway (STAT3, JAK3 variants) is characteristic.

4. General epidemiology

Nasal cavity and middle ear malignancies are relatively rare cancers, accounting for about 3% of all head and neck cancers and less than 0.5% of all malignancies. Sinonasal malignancies worldwide are estimated at about 10,000–20,000 cases per year, and the nasal cavity and paranasal sinuses combined account for 3–5% of head and neck malignancies. They are about twice as frequent in men as in women, with clear occupational clustering among workers in the wood, leather, and nickel industries.

In Korea, nasal cavity and middle ear cancer is a rare cancer, with several hundred cases per year (limited to code C30) in national cancer registry statistics. Nasal NK/T-cell lymphoma occurs relatively more often in East Asia and Latin America than in the West and is an important consideration in the differential diagnosis of nasal malignancies in Korea as well. Middle ear cancer is an extremely rare cancer, accounting for about 0.05% of all head and neck cancers.

5. Pathophysiology

The pathogenesis of nasal cavity and middle ear malignancies varies by cause. Pathogenesis of squamous cell carcinoma: the normal respiratory epithelium of the nasal cavity, nasopharynx, and middle ear mucosa is transformed through squamous metaplasia into dysplastic epithelium by chronic irritation (smoking, pollutants, chronic infection), and DNA damage and repair defects accumulate in dysplastic cells, progressing to invasive squamous cell carcinoma. TP53 variants and CDKN2A loss are the key molecular events.

Pathogenesis of adenocarcinoma: chemicals adsorbed on wood dust or leather dust (quinones, polycyclic aromatic hydrocarbons) directly cause DNA damage in nasal mucosal cells. Adenocarcinoma arises from Bowman's glands (olfactory glands) or submucosal glands of the nasal mucosa, and intestinal-type adenocarcinoma shows features similar to colorectal adenocarcinoma: CDX2 expression, KRAS variants, and APC variants. Pathogenesis of middle ear cancer: repeated inflammation and regeneration due to chronic suppurative otitis media induce squamous metaplasia of the middle ear mucosa, which develops through dysplasia into invasive squamous cell carcinoma.

6. Symptoms

Symptoms of nasal cavity cancer

Early symptoms of nasal cavity cancer resemble treatable benign conditions (nasal polyps, rhinitis), so diagnosis is often delayed. Unilateral nasal obstruction is the most common symptom (about 70–80%), and in most cases unilateral rather than bilateral involvement suggests malignancy. Epistaxis occurs in about 60–70%, and malignancy is suspected when it is recurrent and occurs on one side only. Postnasal drip (mucous or bloody discharge flowing backward), facial pain (trigeminal nerve involvement), and ocular symptoms (diplopia, proptosis, reduced vision) appear in advanced cancer. When the tumor extends into the nasopharynx, otitis media with effusion and conductive hearing loss due to Eustachian tube dysfunction occur.

Symptoms of middle ear cancer

Middle ear cancer resembles the symptoms of chronic otitis media (otorrhea, otalgia), so diagnostic delay is common. With progression, a change in the pattern of chronic otorrhea (bloody otorrhea), otalgia, conductive or sensorineural hearing loss, and facial nerve palsy (CN VII involvement) appear. When the tumor extends into the temporal bone, vertigo and dizziness may accompany.

7. Signs

Nasal endoscopy reveals an intranasal mass (polypoid, ulcerative, or hemorrhagic) and an irregular mucosal surface. Facial examination may show facial asymmetry (swelling of the cheek or periorbital area), proptosis, impaired eye movement (CN III, IV, VI involvement), and sensory abnormalities in the trigeminal nerve distribution. Cervical lymphadenopathy appears in about 10–20% of advanced nasal cavity cancers, mainly palpated at ipsilateral level II (upper jugular). Middle ear examination reveals a retrotympanic mass, tympanic membrane perforation, and bloody otorrhea. Facial nerve palsy is observed when middle ear cancer involves the nerve.

8. Screening

There is no standard general-population screening for nasal cavity and middle ear cancer. However, regular surveillance is recommended for occupational high-risk groups. Annual nasal endoscopy and nasal cytology are recommended for workers exposed to wood or leather dust, and some countries (UK, Netherlands) operate occupational cancer surveillance programs for high-risk groups exposed to wood dust. Personal protective equipment to prevent occupational exposure (dust masks, N95 or higher) and improvement of the work environment (local exhaust ventilation systems) are central to primary prevention. Patients with inverted papilloma need regular nasal endoscopic follow-up. Appropriate treatment and regular otolaryngologic follow-up of patients with chronic otitis media contribute to early detection of middle ear cancer.

9. Diagnosis

Endoscopy and imaging

Nasal endoscopy is used to observe intranasal lesions directly and perform biopsy. Skull base CT evaluates bone invasion, the extent of paranasal sinus involvement, and skull base invasion. Cranial and head and neck MRI is superior for evaluating soft tissue invasion, dural invasion, cavernous sinus invasion, and perineural invasion. PET-CT is used to evaluate cervical lymph node metastasis and distant metastasis. For middle ear cancer, temporal bone CT (thin-slice) and MRI are used together.

Pathology and staging

After the histologic type is confirmed on biopsy tissue, detailed classification is made by immunohistochemistry (p16, CK7, CK20, CDX2, synaptophysin, etc.). HPV status is confirmed by p16 IHC and HPV in-situ hybridization. AJCC TNM 8th edition staging is used, with different classification systems for the nasal cavity/maxillary sinus and the middle ear. For nasal cavity cancer, the Pearson classification and others are also used.

10. Treatment

Surgical treatment

Surgery is the central treatment for nasal cavity cancer amenable to curative resection. Endoscopic resection achieves resection rates equivalent to open surgery for T1–T2 and some T3 lesions, with better functional preservation (nasal drainage and facial function). Advanced cancer of T4 or higher may require craniofacial resection. For middle ear cancer, temporal bone resection is classified by extent into external auditory canal resection, subtotal temporal bone resection, and total temporal bone resection.

Radiation and chemotherapy

Adjuvant radiotherapy is recommended after surgery with positive margins, perineural invasion, or lymph node metastasis. For advanced unresectable nasal cavity cancer, cisplatin-based concurrent chemoradiotherapy (CCRT) is standard. Proton therapy and carbon ion therapy are promising radiotherapy methods that achieve high local control rates while minimizing normal tissue toxicity in sinonasal cancers invading the skull base. In nasal malignant melanoma, postoperative immunotherapy (nivolumab, pembrolizumab) or BRAF/MEK inhibitors (when BRAF is mutated) are used. In nasal NK/T-cell lymphoma, L-asparaginase-based chemotherapy is combined with radiotherapy.

11. Prognosis

The prognosis of nasal cavity cancer varies by stage, histologic type, and primary site. For squamous cell carcinoma, overall 5-year survival is about 50–60% (higher in early stages). For intestinal-type adenocarcinoma (intestinal-type nasal adenocarcinoma, ITAC), 5-year survival is 40–60% depending on histologic differentiation. For esthesioneuroblastoma, 5-year survival by Kadish stage is reported as ~90% for stage A, ~70% for B, ~50% for C, and ~20% for D. Nasal malignant melanoma has a very poor prognosis, with 5-year survival of only 10–30%. Middle ear cancer is also often already advanced at diagnosis, with a poor 5-year survival of about 20–50%. HPV-positive nasal squamous cell carcinoma has a better treatment response and prognosis than HPV-negative disease.

12. Prevention

Blocking occupational exposure: for workers exposed to wood, leather, and nickel dust, wearing personal protective equipment (dust masks, N95 or higher), improving the work environment (local exhaust, wet work methods), and complying with occupational exposure limits (OEL) are the most effective ways to prevent nasal adenocarcinoma. Smoking cessation: reduces the risk of smoking-related nasal squamous cell carcinoma. Treatment of chronic otitis media: persistent otitis media is managed with appropriate antibiotic therapy, myringotomy with tube insertion, and if necessary surgery (mastoidectomy) to lower the risk of middle ear cancer. Active treatment of inverted papilloma: complete resection and regular endoscopic follow-up. HPV vaccination may also contribute indirectly to preventing HPV-related nasal cancer.


13. References

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2025. Fort Washington, PA: NCCN; 2025.
  2. Acheson ED, Cowdell RH, Hadfield E, Macbeth RG. Nasal cancer in woodworkers in the furniture industry. Br Med J. 1968;2(5605):587-596.
  3. Luce D, Leclerc A, Begin D, et al. Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control. 2002;13(2):147-157.
  4. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):877-885.
  5. Licitra L, Suardi S, Bossi P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol. 2004;22(24):4901-4906.
  6. Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147(1):7-14.
  7. Kim BS, Kim SH, Kim TM, et al. Treatment outcome and prognosis of nasal NK/T-cell lymphoma. Ann Hematol. 2009;88(2):163-169.
  8. Smee RI, Broadley K, Bridger GP, Kwok B. Carcinomas of the middle ear. ANZ J Surg. 2011;81(12):884-888.
  9. Bossi P, Saba NF, Vermorken JB, et al. The role of systemic therapy in the management of sinonasal cancer: a critical review. Cancer Treat Rev. 2015;41(10):836-843.
  10. Mendenhall WM, Amdur RJ, Stringer SP, et al. Radiation therapy for squamous cell carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009;119(3):509-517.